Resources from the same session
Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
Presenter: Michael Friedlander
Session: Proffered paper session - Gynaecological cancers
Resources:
Slides
225O - Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy
Presenter: Michael Friedlander
Session: Proffered paper session - Gynaecological cancers
Resources:
Abstract
Prevalence of germline BRCA1 and BRCA2 mutations and variants among ovarian, primary peritoneal and fallopian tube cancer patients: A multicentre Indian study
Presenter: Sudeep Gupta
Session: Proffered paper session - Gynaecological cancers
Resources:
Slides
LBA10 - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Presenter: Keiichi Fujiwara
Session: Proffered paper session - Gynaecological cancers
Resources:
Abstract
Slides
Invited Discussant 224O, 225O and LBA10
Presenter: Cristiana Sessa
Session: Proffered paper session - Gynaecological cancers
Resources:
Slides
LBA11 - Mainstreaming genetic counselling for genetic testing of BRCA1/2 in ovarian cancer patients in Malaysia (MaGIC study)
Presenter: Sook Yee Yoon
Session: Proffered paper session - Gynaecological cancers
Resources:
Abstract
Slides